Figure 4.
Effects of different times of preincubation with BTKi’s on platelet aggregation after FcγRIIA stimulation by cross-linking. (A) Blood samples were preincubated for 5, 15, 30, or 60 minutes with solvent (DMSO, 0.1%) or BTKi’s (ibrutinib, acalabrutinib, tirabrutinib, zanubrutinib, or evobrutinib) before incubation with AT10 (2 µg/mL) for 3 minutes and stimulation with Fab2 (30 µg/mL) for 10 minutes. Values are mean ± SD (n = 6). (B) Preincubation for 15 or 60 minutes with 2 concentrations of fenebrutinib before stimulation with AT10 and Fab2. Values are mean ± SD (n = 5). *P < .05; ***P < .001; ++P < .01; +++P < .001. ns, not significant. 

Effects of different times of preincubation with BTKi’s on platelet aggregation after FcγRIIA stimulation by cross-linking. (A) Blood samples were preincubated for 5, 15, 30, or 60 minutes with solvent (DMSO, 0.1%) or BTKi’s (ibrutinib, acalabrutinib, tirabrutinib, zanubrutinib, or evobrutinib) before incubation with AT10 (2 µg/mL) for 3 minutes and stimulation with Fab2 (30 µg/mL) for 10 minutes. Values are mean ± SD (n = 6). (B) Preincubation for 15 or 60 minutes with 2 concentrations of fenebrutinib before stimulation with AT10 and Fab2. Values are mean ± SD (n = 5). *P < .05; ***P < .001; ++P < .01; +++P < .001. ns, not significant. 

Close Modal

or Create an Account

Close Modal
Close Modal